• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Exploreatory research of drug resistance mechanisms based on exosome information in the cancer microenvironment

Research Project

Project/Area Number 20K09043
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 55020:Digestive surgery-related
Research InstitutionWakayama Medical University

Principal Investigator

Ueno Masaki  和歌山県立医科大学, 医学部, 准教授 (90405465)

Co-Investigator(Kenkyū-buntansha) 速水 晋也  和歌山県立医科大学, 医学部, 講師 (00468290)
山上 裕機  和歌山県立医科大学, 医学部, 学長特命教員(特別顧問) (20191190)
川井 学  和歌山県立医科大学, 医学部, 教授 (40398459)
Project Period (FY) 2020-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2021: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords肝細胞癌 / 免疫チェックポイント阻害剤 / 癌微小環境 / 肝内胆管癌 / エクソソーム
Outline of Research at the Start

近年、癌細胞周辺に存在する癌関連線維芽細胞(cancer associated fibroblast; CAF)
が癌の増殖・転移や薬剤耐性に関与しているといわれるようになった。癌細胞は、CAFとの
クロストークの中で、周辺微小環境を癌にとって好ましい状態するように働きかけているこ
とがわかり、その情報伝達手段の一つとしてエクソソームが用いられている。
本研究では、特に抗癌剤に対する薬剤耐性の発生機序に関して、エクソソームが内包する情報の変化の観点からそのメカニズムを探索することを目的とする

Outline of Final Research Achievements

In the microenvironment of hepatocellular carcinoma, the relationship between the expression of various proteins in tumors and the expression of immune system cytokines was analyzed, and it some subclass classification was confirmed that there were some tumor clusters with strong immunogenicity. Meanwhile, in clinical cases performing atezolizumab and bevacizumab, the effectiveness of the treatment could be predicted from tumor characteristics and serum parameters. Alpha-fetoprotein (AFP), C-reactive protein (CRP), and neutrophil-to-lymphocyte ratio (NLR) were extracted as significant predictive factors. The factors reflecting the host condition, such as CRP and NLR, as well as the malignancy of the tumor itself, also affected the effectiveness of these drug therapies.

Academic Significance and Societal Importance of the Research Achievements

肝細胞癌の癌微小環境において、多様な遺伝変異と相関して、腫瘍の免疫原性も多様であり、周辺の免疫担当細胞の分布も多様であることが分かった。免疫チェックポイント阻害剤を用いた治療を行う際は、このような腫瘍自体の多様性と免疫原性の程度を評価するとともに、患者自身の抗腫瘍免疫状態も効果に影響を及ぼすことが分かり、宿主側の環境因子も今後調査する必要性があることが分かった。

Report

(5 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (7 results)

All 2024 2023 2022 2020

All Journal Article (4 results) (of which Peer Reviewed: 4 results,  Open Access: 1 results) Presentation (3 results)

  • [Journal Article] Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer2024

    • Author(s)
      Motobayashi Hideki、Kitahata Yuji、Okada Ken-ichi、Miyazawa Motoki、Ueno Masaki、Hayami Shinya、Miyamoto Atsushi、Shimizu Atsushi、Sato Masatoshi、Yoshimura Tomohiro、Nakamura Yuki、Takemoto Norio、Nakai Tomoki、Hyo Takahiko、Matsumoto Kyohei、Yamaue Hiroki、Kawai Manabu
    • Journal Title

      Journal of Cancer Research and Clinical Oncology

      Volume: 150 Issue: 2 Pages: 35-35

    • DOI

      10.1007/s00432-023-05594-1

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Response Prediction Model of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Retrospective Study2023

    • Author(s)
      Ueno Masaki、Kosaka Hisashi、Iida Hiroya、Ida Yoshiyuki、Aoi Kazunori、Mori Haruki、Miyamoto Atsushi、Nishida Yuko、Hayami Shinya、Kawai Manabu、Kaibori Masaki
    • Journal Title

      Oncology

      Volume: 101 Issue: 9 Pages: 565-574

    • DOI

      10.1159/000531317

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Radiological Shape of the Tumor Predicts Progression and Survival in Resected Extrahepatic Cholangiocarcinoma.2023

    • Author(s)
      Okada KI, Kawai M, Hirono S, Miyazawa M, Kitahata Y, Ueno M, Hayami S, Ikoma A, Sonomura T, Wan K, Shimokawa T, Yamaue H.
    • Journal Title

      J Gastrointest Surg

      Volume: - Issue: 6 Pages: 1113-1121

    • DOI

      10.1007/s11605-023-05614-y

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy.2022

    • Author(s)
      Kitahata Y, Kawai M, Hirono S, Okada KI, Miyazawa M, Motobayashi H, Ueno M, Hayami S, Miyamoto A, Yamaue H.
    • Journal Title

      Ann Surg Oncol.

      Volume: 29 Issue: 3 Pages: 1596-1605

    • DOI

      10.1245/s10434-021-10985-0

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Presentation] 肝細胞癌に対するatezolizumab+ bevacizumab 治療:宿主の免疫能と治療効果について2022

    • Author(s)
      宮本篤、上野昌樹、他
    • Organizer
      第54回制癌剤適応研究会
    • Related Report
      2021 Research-status Report
  • [Presentation] 肝細胞癌におけるSETD8の高発現と予後の関連2020

    • Author(s)
      須崎紀彦、上野昌樹、他
    • Organizer
      第79回日本癌学会総会
    • Related Report
      2020 Research-status Report
  • [Presentation] 術後3ヵ月目のALBI scoreはより鋭敏に肝細胞癌切除後の予後を反映する2020

    • Author(s)
      宮本篤、上野昌樹、他
    • Organizer
      日本臨床外科学会
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi